
Featured
Eli Lilly's Retatrutide Delivers Record 30% Weight Loss in Trials
Eli Lilly’s retatrutide delivered up to 30% weight loss in Phase 3 obesity trials, outperforming Wegovy and other GLP-1 therapies.
Siddharth•Invalid Date
3 articles tagged

Eli Lilly’s retatrutide delivered up to 30% weight loss in Phase 3 obesity trials, outperforming Wegovy and other GLP-1 therapies.

Novo Nordisk is using AI in India to speed up obesity drug launches, regulatory filings, and oral Wegovy development globally.

Discover 13 surprising GLP-1 benefits beyond diabetes and weight loss, including heart health, brain function, and reduced inflammation.